Table 2. Ongoing clinical trials involving anti-PD-1/PD-L1 in combination with NK cell-based therapy.

Trial identifier	Phase	Participants	Intervention/treatment	Condition or diseases	Status
PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand; IL, interleukin; DC, dendritic cell; NK, natural killer; CAR, chimeric antigen receptor.
NCT05334329	Phase 1	21	Umbilical cord blood natural killer cells (CB-NK) expressing soluble IL-15 (sIL-15) and PD-L1 +/− atezolizumab	Advanced/metastatic/recurrent/refractory non-small cell lung carcinoma	Recruiting
NCT05461235	Phase 2	/	Anti-PD-1 antibody combined with autologous DC or NK cells	Digestive carcinoma	Not yet recruiting
NCT03383978	Phase 1	42	Intracranial injection of NK-92/5.28.z cells in combination with the anti-PD-1 antibody ezabenlimab (BI 754091)	Glioblastoma	Recruiting
NCT04847466	Phase 2	55	Irradiated PD-L1 CAR-NK cells plus pembrolizumab plus N-803	Recurrent/metastatic gastric or head and neck cancer	Recruiting
NCT04050709	Phase 1	16	PD-L1 t-haNK	Locally advanced or metastatic solid cancers	Active, not recruiting
NCT04927884	Phase 1, Phase 2	79	Sacituzumab plus cyclophosphamide, N-803, and PD-L1 t-haNK	Advanced triple negative breast cancer	Active, not recruiting
NCT04390399	Phase 2	328	Standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with aldoxorubicin HCl, N-803, and PD-L1 t-haNK	Pancreatic cancer	Recruiting
NCT03228667	Phase 2	145	PD-1/PD-L1 checkpoint inhibitor, N-803, and PD-L1 t-haNK cellular therapy	Patients who have previously received treatment with PD-1/PD-L1 immune checkpoint inhibitors	Active, not recruiting